Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 8Head & Neck 4Gynecologic 3Gastrointestinal 3CNS 3Thoracic 2Other hematologic neoplasm 2Tumor-Agnostic 1Sarcoma 1Myeloid 1Genitourinary 1Breast 1

Conditions

Small Cell Lung Carcinoma 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1

Interventions

pembrolizumab 159Carboplatin 147Cisplatin 130Pemetrexed 103Paclitaxel 89Nivolumab 71Radiotherapy 69Docetaxel 62Erlotinib Hydrochloride 58Gemcitabine 57Etoposide 44osimertinib 43Bevacizumab 43Cyclophosphamide 42durvalumab 41atezolizumab 35Cetuximab 33Radiosurgery 26130-nm albumin-bound paclitaxel 26fludarabine 23Ipilimumab 23Radiation 21Magnetic Resonance Spectroscopy 21Irinotecan 21Taxes 20Oxaliplatin 20Fluorouracil 20Gefitinib 19Everolimus 19Topotecan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × adavosertib × Thoracic × Clear all
NCT02482311 2023-07-03

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
92 enrolled
BreastGynecologicThoracic

Ovarian Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02511795 2019-11-07

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

AstraZeneca

Phase 1 Completed
128 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡